Research advances in hepatocellular carcinoma immunotherapy

CHEN Heng-kai; LIU Xiao-long

doi:10.3969/j.issn.2096-3351.2021.06.003

您当前的位置：

首页 >

文章列表页 >

Research advances in hepatocellular carcinoma immunotherapy

更新时间：2023-04-16

- Research advances in hepatocellular carcinoma immunotherapy
- Journal of Southwest Medical University Vol. 44, Issue 6, Pages: 601-606(2021)
- 作者机构：
  
  1. 福建医科大学孟超肝胆医院肝胆外科,福州,350025
  2. 福建省联合创新重点实验室,福州,350025
- 作者简介：
- 基金信息：
- DOI：10.3969/j.issn.2096-3351.2021.06.003
  CLC：
- Published：2021，
  
  Published Online：20 November 2021，
扫描看全文
CHEN Heng-kai, LIU Xiao-long. Research advances in hepatocellular carcinoma immunotherapy. [J]. Journal of Southwest Medical University 44(6):601-606(2021)
DOI：

CHEN Heng-kai, LIU Xiao-long. Research advances in hepatocellular carcinoma immunotherapy. [J]. Journal of Southwest Medical University 44(6):601-606(2021) DOI： 10.3969/j.issn.2096-3351.2021.06.003.

摘要

肝细胞癌(hepatocellularcarcinoma，HCC)是人类最常见的恶性肿瘤之一，易复发转移，预后差。近年来，以免疫检查点抑制疗法为代表的免疫治疗已经在HCC病人中显示出强大的抗肿瘤能力，尤其是与酪氨酸激酶抑制剂或放疗等治疗措施联用可显著提升HCC的客观缓解率，临床应用前景良好。同时，包括CAR-T细胞治疗、新抗原疫苗等新一代免疫疗法也在HCC治疗中展现较好的应用前景。

Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in human

which is prone to recurrence metastasis and with poor therapeutil outcomes. Recently

immunotherapies

represented by im⁃mune checkpoint inhibitors (ICIs)

have demonstrated robust antitumor effects in patients with HCC; particularly

combination therapies of ICIs with tyrosine kinase inhibitors or radiotherapy can significantly improve the objective response rate

showing promise in clinical applications. Meanwhile

the new-generation immunotherapies including CAR-T therapy and neoantigen vaccine also have shown great promise for HCC treatment.

关键词

肝细胞癌免疫治疗免疫检测点抑制剂联合治疗

Keywords

Hepatocellular carcinomaImmunotherapyCheckpoint InhibitorCombination therapy

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Research progress of CAR-T cell immunotherapy in solid tumors

Progress of chimeric antigen receptor T cell immunotherapy in refractory/relapse hematologic malignancies

Mechanism of liver cancer-associated zinc finger protein/transcription factor disorders and their clinical value

Progress in multimodality therapy for primary hepatocellular carcinoma unsuitable for surgery

Research progress in the effects of medical treatment of malignant tumors on thyroid function

Related Author

JIA Yiwei

FENG Cong

SUN Shiyu

MA Xingcong

ZHANG Shuqun

WANG Xiaman

YANG Yun

HE Aili

Related Institution

Department of Oncology，The Second Affiliated Hospital of Xi'an Jiaotong University

Department of Hematology, the Second Affiliated Hospital of Medical College of Xi'an Jiaotong University

Research Center of Clinical Medicine，the Affiliated Hospital of Nantong University

Department of Immunology，Medical School of Nantong University

Southwestern Medical University

⁰